Pub. Date : 2015 Dec
PMID : 26616595
4 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin. | Metformin | dipeptidyl peptidase 4 | Homo sapiens |
| 2 | BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitor add-on therapy is a new option for patients with inadequately controlled type 2 diabetes who are taking combined metformin and sulfonylurea (SU). | Metformin | dipeptidyl peptidase 4 | Homo sapiens |
| 3 | BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitor add-on therapy is a new option for patients with inadequately controlled type 2 diabetes who are taking combined metformin and sulfonylurea (SU). | Metformin | dipeptidyl peptidase 4 | Homo sapiens |
| 4 | METHODS: We included 807 patients with type 2 diabetes who were prescribed a newly added DPP-4 inhibitor to ongoing metformin and SU in 2009 to 2011. | Metformin | dipeptidyl peptidase 4 | Homo sapiens |